Human ENT2 (SLC29A2) activation kit by CRISPRa

CAT#: GA102168

SLC29A2 CRISPRa kit - CRISPR gene activation of human solute carrier family 29 member 2



  See Other Versions

CNY 12,255.00


货期*
4周

规格
    • 1 kit

Product images

经常一起买 (3)
SLC29A2 rabbit polyclonal antibody
    • 100 ul

CNY 1,999.00
CNY 3,280.00


SLC29A2 (Myc-DDK-tagged)-Human solute carrier family 29 (nucleoside transporters), member 2 (SLC29A2)
    • 10 ug

CNY 3,656.00
CNY 3,990.00


ENT2 Rabbit monoclonal Antibody
    • 100 ul

CNY 1,999.00
CNY 3,280.00

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol SLC29A2
Locus ID 3177
Kit Components

GA102168G1, ENT2 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA102168G2, ENT2 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA102168G3, ENT2 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPRa SAM technology. The efficiency of the activation can be affected by many factors, including nucleosome occupancy status, chromatin structure and the gene expression level of the target, etc.
Reference Data
RefSeq NM_001300868, NM_001300869, NM_001532, NR_125343
Synonyms DER12; ENT2; HNP36
Summary The uptake of nucleosides by transporters, such as SLC29A2, is essential for nucleotide synthesis by salvage pathways in cells that lack de novo biosynthetic pathways. Nucleoside transport also plays a key role in the regulation of many physiologic processes through its effect on adenosine concentration at the cell surface (Griffiths et al., 1997 [PubMed 9396714]).[supplied by OMIM, Nov 2008]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...